Plain-English translation of NCT06900647 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether bortezomib and cisplatin work well together to treat breast cancer that has come back or spread. Researchers want to find the right doses of these two medications that are both safe and effective, starting with lower doses and gradually increasing them as they learn more.
Many women with advanced breast cancer need new treatment options when standard therapies stop working. This study is exploring whether combining these two medications in a new way might help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of the two medications through a vein, with doses increasing step-by-step as researchers monitor your safety and how well the treatment works. The study involves about 20 patients total, and you would have regular blood tests and scans to check your health and how your cancer responds to treatment. Researchers will watch carefully for any side effects and adjust the doses as needed to find the safest and most effective combination.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Sun Yat-sen University
Enrollment target
~20 participants
Started
January 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yanxia Shi, Doctor
Sun Yat-sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.